Related references
Note: Only part of the references are listed.Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma
Yair Herishanu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
How I treat cold agglutinin disease
Sigbjorn Berentsen
BLOOD (2021)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects
Bruno Fattizzo et al.
FRONTIERS IN ONCOLOGY (2020)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment
Quentin A. Hill et al.
BLOOD ADVANCES (2019)
Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia
Jonathan Feld et al.
ACTA HAEMATOLOGICA (2019)
Refractory Autoimmune Cytopenias Treated With Venetoclax
Max J. Gordon et al.
HEMASPHERE (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre
Paul J. Hampel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Current and emerging treatment options for autoimmune hemolytic anemia
Wilma Barcellini et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia
Alejandro Garcia-Horton et al.
BLOOD (2018)
Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)
Sophie Godet et al.
BLOOD (2018)
The diagnosis and management of primary autoimmune haemolytic anaemia
Quentin A. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
M. Montillo et al.
BLOOD CANCER JOURNAL (2017)
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Mazie Tsang et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
Marcelo Pitombeira de Lacerda et al.
ANNALS OF HEMATOLOGY (2017)
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
Alienor Galinier et al.
CASE REPORTS IN ONCOLOGY (2017)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia
Tom G. Rider et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion
Francesco Cavazzini et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Secondary autoimmune cytopenias in chronic lymphocytic leukemia
Kerry A. Rogers et al.
SEMINARS IN ONCOLOGY (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)
Anne Quinquenel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia
Sudhir Manda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
Anne Quinquenel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Autoimmune cytopenias in chronic lymphocytic leukemia
Carlo Visco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia
J. Rossignol et al.
LEUKEMIA (2011)
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status
Carlo Visco et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia
Matthew Kaufman et al.
LEUKEMIA & LYMPHOMA (2009)
Disease-Specific Complications of Chronic Lymphocytic Leukemia
C. Dearden
Hematology-American Society of Hematology Education Program (2008)
The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia
Gulsum Emel Pamuk et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
Giovanni D'Arena et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Share Paper
